Dare Bioscience, Inc. (DARE)
DARE moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How DARE actually reacts to news — the realized, point-in-time move the market made, measured across 241 labeled events over the last three years with zero look-ahead.
DARE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 237 |
| 30-min | 0.00% | 43% | 241 |
| 60-min | 0.00% | 51% | 241 |
| to close | 0.00% | 43% | 240 |
| Middle 50% of DARE reactions | -1.79% to +1.42% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 241 |
Half of all Dare Bioscience, Inc. news events land between -1.79% and +1.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DARE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DARE's baseline. Nothing else.
Recent DARE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities | Press release | GlobeNewswire | +0.00% | -4.87% | |
| Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting | Press release | GlobeNewswire | +0.09% | -1.78% | |
| Form DEF 14A Dare Bioscience, Inc. For: Oct 06 | SEC filing · Form DEF | SEC EDGAR | -1.63% | -2.98% | |
| Form 8-K Dare Bioscience, Inc. For: Sep 28 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | -0.23% | |
| Form 8-K Dare Bioscience, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +1.17% | -1.05% | |
| Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection | Press release | GlobeNewswire | +2.53% | -5.06% | |
| Form PRE 14A Dare Bioscience, Inc. For: Sep 23 | SEC filing · Form PRE | SEC EDGAR | +2.19% | -7.70% | |
| Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil | Press release | GlobeNewswire | +0.00% | +4.23% | |
| Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand | Press release | GlobeNewswire | -0.98% | -1.53% | |
| Form 8-K Dare Bioscience, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.23% | |
| Form 8-K Dare Bioscience, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | -1.70% | |
| Form EFFECT Dare Bioscience, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.16% | +3.00% | |
| Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth | Press release | GlobeNewswire | +0.00% | +0.13% | |
| Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series | Press release | GlobeNewswire | +0.13% | -1.64% | |
| Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society | Press release | GlobeNewswire | -0.38% | -9.91% | |
| Form S-1 Dare Bioscience, Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.13% | -1.64% | |
| Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment | Press release | GlobeNewswire | -0.79% | +0.33% | |
| Form D Dare Bioscience, Inc. | SEC filing · Form D | SEC EDGAR | -1.20% | -1.32% | |
| Form 253G2 Dare Bioscience, Inc. | SEC filing · Form 253G2 | SEC EDGAR | -1.20% | -1.32% | |
| DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List | Press release | GlobeNewswire | -3.54% | -6.88% | |
| Form 8-K Dare Bioscience, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -7.40% | -12.79% | |
| Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -23.92% | -28.87% | |
| Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances | Press release | GlobeNewswire | -4.39% | -40.00% | |
| Form 10-Q Dare Bioscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.39% | -40.00% | |
| Form 8-K Dare Bioscience, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -4.39% | -40.00% | |
| Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 | Press release | GlobeNewswire | -1.88% | +0.00% | |
| Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx | Press release | GlobeNewswire | -1.91% | -9.54% | |
| Form 8-K Dare Bioscience, Inc. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -1.95% | +0.00% | |
| Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities | Press release | GlobeNewswire | -1.03% | -30.93% | |
| Form 253G2 Dare Bioscience, Inc. | SEC filing · Form 253G2 | SEC EDGAR | -1.03% | -30.93% | |
| Form 8-K Dare Bioscience, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -1.03% | -30.93% | |
| Form 8-K Dare Bioscience, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +4.50% | |
| Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event | Press release | GlobeNewswire | -1.48% | +1.97% | |
| Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform | Press release | GlobeNewswire | +2.79% | +0.96% | |
| Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment | Press release | GlobeNewswire | +0.00% | -4.76% | |
| Form S-8 Dare Bioscience, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.23% | +1.96% | |
| Form 8-K Dare Bioscience, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | -0.68% | -6.82% | |
| Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 | Press release | GlobeNewswire | +0.00% | +4.33% | |
| Form 8-K Dare Bioscience, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.49% | -1.49% | |
| Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules | Press release | GlobeNewswire | +3.48% | +8.46% | |
| Form DEFA14A Dare Bioscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.90% | -1.35% | |
| Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer | Press release | GlobeNewswire | -0.76% | +0.00% | |
| Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies | Press release | GlobeNewswire | +1.91% | +0.48% | |
| Form 8-K Dare Bioscience, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | +8.17% | |
| Form 253G2 Dare Bioscience, Inc. | SEC filing · Form 253G2 | SEC EDGAR | +0.00% | -1.36% | |
| Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -1.36% | |
| Form 10-Q Dare Bioscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -1.36% | |
| Form 8-K Dare Bioscience, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.36% | |
| Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive | Press release | GlobeNewswire | +0.00% | +8.68% | |
| Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 | Press release | GlobeNewswire | -3.93% | -4.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DARE section they belong to.
Where else DARE is measured.
DARE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| IKANG HEALTH CARE GROUP (KANG) | 242 | -0.07% | 44% |
| Adial Pharmaceuticals, Inc (ADIL) | 241 | 0.00% | 44% |
| Genprex, Inc. (GNPX) | 241 | -1.17% | 33% |
| Allakos Inc. (ALLK) | 240 | -0.70% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Dare Bioscience, Inc.'s median reaction calculated?
Every labeled DARE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 241 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of DARE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DARE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.